97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof
#902B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins
#903METHODS AND COMPOSITIONS FOR NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
#904ANTI-B7H4 ANTIBODY, AND BISPECIFIC ANTIBODY AND USE THEREOF
#905Anti-B7H3 Antibodies for the Treatment of Cancer
#906MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#907ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#908CHIMERIC MYD88 RECEPTORS FOR REDIRECTING IMMUNOSUPPRESSIVE SIGNALING AND RELATED COMPOSITIONS AND METHODS
#909DRUG FOR TREATING TUMOR
#910Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#911CELL LOCALIZATION SIGNATURE AND IMMUNOTHERAPY
#912PD-L1 BINDING AGENTS AND USES THEREOF
#913MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF
#914Antiaging effect of Intradermal Administration of Immune Checkpoint Inhibitors
#915METHODS AND COMPOSITIONS FOR INDUCTION OF ANTITUMOR IMMUNITY
#916COMBINATIONS FOR THE TREATMENT OF CANCER
#917OX40-TARGETED ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#918PD-1 AND PD-L1 BINDING AGENTS
#919SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
#920STRENGTHENED RECEPTOR FOR IMPROVING IMMUNE CELL FUNCTION
#921Composition and method of use recombinant fusion protein to generate CAR-immune cells
#922METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS
#923BINDING PROTEIN IN FAB-HCAB STRUCTURE
#924ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#925ANTI-PD-L1 ANTIBODY AND USE THEREOF
#926BIFUNCTIONAL MOLECULES TARGETING PD-L1 AND TGF-BETA
#927PD-L1/LAG-3 BISPECIFIC ANTIBODY FORMULATION AND PREPARATION METHOD THEREFOR AND USE THEREOF
#928B7-H4 ANTIBODY DOSING REGIMENS
#929ANTI-PD-L1 ANTIBODY PREPARATION
#930INTRATUMORALLY INJECTED YEAST VACCINE
#931ANTI-CD277 ANTIBODIES AND USES THEREOF
#932USE OF CSF-1R KINASE INHIBITOR
#933ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
#934COMBINATION OF AN ATP-HYDROLYZING ENZYME AND AN IMMUNE CHECKPOINT MODULATOR AND USES THEREOF
#935SINGLE VARIABLE DOMAIN ANTIBODY TARGETING HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) AND DERIVATIVE THEREOF
#936THERAPEUTIC SIRP-ALPHA ANTIBODIES
#937ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#938FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE
#939METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
#940Polypeptide-antibody complexes and uses thereof
#941ANTI-CD137 ANTIGEN-BINDING MOLECULE FOR USE IN CANCER TREATMENT
#942B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES
#943COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER
#944ANTI-VISTA ANTIBODIES AND USES THEREOF
#945SERUM HALF-LIFE EXTENDED PD-L1 INHIBITORY POLYPEPTIDES
#946ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS
#947HUMAN MONOCLONAL ANTIBODIES AGAINST TIGIT FOR IMMUNE RELATED DISEASES
#948Monoclonal antibody binding to TIGIT antigen, preparation method and use thereof
#949Method of treating cancer using disulfide-linked trimeric OX40L
#950FC-EPSILON CAR
#951Inhibitors of the Artemin Pathway for Treatment of Cancer
#952METHODS OF TREATING CANCER WITH A STING AGONIST
#953RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME
#954METHODS AND COMPOSITIONS FOR MODULATING ARGININE LEVELS IN IMMUNE CELLS
#955ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION
#956COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
#957DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS
#958UVEAL MELANOMA TREATMENT USING SEA-CD40
#959ANTI-CD28 COMPOSITIONS
#960ANTI-PDL1 x EGFR BISPECIFIC ANTIBODY
#961PPHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND EGFR, NKG2D, AND CD16
#962Materials And Methods For Binding Siglec-3/CD33
#963MULTIMERS FOR VIRAL STRAIN EVOLUTION
#964RECEPTOR FOR VISTA
#965Bifunctional molecule and use thereof
#966POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME
#967COMBINATION THERAPY INVOLVING ANTI-CD39 ANTIBODIES AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES
#968DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#9694-1BB-BINDING PROTEIN AND USE THEREOF
#970A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF
#971IL-15-based molecules and methods of treating a neoplasia
#972Method of treating cancer with composition comprising IL-15-based molecules and BCG
#973Method for Treating Melanoma
#974ANTI-CD93 CONSTRUCTS AND USES THEREOF
#975BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN
#976TARGETED BINDING AGENTS AGAINST B7-H1
#977Binding Members to PD-L1
#978NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
#979Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex
#980MULTIMERIC IMMUNOMODULATOR TARGETING 4-1BB
#981SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT
#982PD-L1-SPECIFIC ANTIBODY AND ANTI-PD-L1-CAR-T CELLS
#983COMBINATION DRUG FOR TREATING KIDNEY CANCER
#984METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION
#985FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
#986PILRA ANTIBODIES AND METHODS OF USE THEREOF
#987IMMUNOMODULATING TREATMENTS OF BODY CAVITIES
#988ANTI-B7-H3 ANTIBODY AND PREPARATION THEREFOR AND USE THEREOF
#989MULTI-SPECIFIC IMMUNE MODULATORS
#990PD-1/PD-L1 INHIBITORS
#991METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#992ANTI-PD-L1 AND PD-L2 ANTIBODY AND DERIVATIVES AND USE THEREOF
#993B7H3-TARGETING PROTEINS AND METHODS OF USE THEREOF
#994IMMUNOSTIMULATORY MULTIMERIC BINDING MOLECULES
#995ANTI-PD-L1 ANTIBODIES
#996IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#997COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY
#998TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
#999Anti-LY6H antibodies and antibody drug conjugates
#1000DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER
#1001METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY
#1002ANTIBODIES BINDING 4-1BB AND USES THEREOF
#1003ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF
#1004Antibodies Binding to Vista at Acidic pH
#1005MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#1006Virus composition
#1007TIGIT ANTIBODIES, ENCODING NUCLEIC ACIDS AND METHODS OF USING SAID ANTIBODIES IN VIVO
#1008HUMAN IL-15 MUTANT AND USES THEREOF
#1009Anti-TIGIT Antibodies
#1010Compositions comprising IL-15-based molecules and immune checkpoint inhibitor antibodies
#1011VIP Antagonists and Uses in Treating Cancer
#1012PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF
#1013PROPHYLACTIC OR THERAPEUTIC AGENT FOR AT LEAST ONE TYPE OF CANCER SELECTED FROM GROUP CONSISTING OF PANCREATIC CANCER, LUNG CANCER, COLORECTAL CANCER, CHOLANGIOCARCINOMA AND LIVER CANCER, PROPHYLACTIC OR THERAPEUTIC AGENT FOR SAID CANCER WHICH IS USED IN COMBINATION DRUG IN COMBINATION WITH SAID AGENT, COMBINATION DRUG COMPRISING SAID AGENTS, AND METHOD FOR SCREENING FOR PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER
#1014BISPECIFIC ANTIBODY TARGETING HUMAN CLAUDIN AND HUMAN PDL1 PROTEINS, AND APPLICATION THEREOF
#1015A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL
#1016Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
#1017PURIFICATION OF ANTIBODIES
#1018Anti-TIGIT Antibodies
#1019USE OF EZH2 INHIBITORS FOR TREATING CANCER
#1020B7-H3 CHIMERIC ANTIGEN RECEPTORS
#1021Antibodies Binding to ILT4
#1022A PROTEIN COMPLEX COMPRISING AN IMMUNOCYTOKINE
#1023BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
#1024DEFORMABLE HYDROGEL PARTICLES AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME
#1025SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION
#1026SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION
#1027COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
#1028GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD276
#1029ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF
#1030CARRIER-PD-L1 BINDING AGENT COMPOSITIONS FOR TREATING CANCERS
#1031MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
#1032Conjugates of Biomolecule and Use Thereof
#1033STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY
#1034COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
#1035REDUCED CALORIC INTAKE AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
#1036Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus
#1037BINDING MOLECULES TO CD38 AND PD-L1
#1038Neoepitope vaccine and immune stimulant combinations and methods
#1039ANTI-PD-L1 ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#1040Substituted aminothiazoles as DGKzeta inhibitors for immune activation
#1041CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#1042PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
#1043sPD-1 VARIANT – FC FUSION PROTEINS
#1044PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#1045COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4
#1046TARGETING TIM-3 AND LAG-3 RECEPTORS INDUCED BY CD44+ CD90+ CANCER STEM CELLS IN SMALL CELL LUNG CANCER
#1047ANTIBODIES AGAINST PD-L1 AND METHODS OF USE THEREOF
#1048MULTISPECIFIC ANTI-CLAUDIN-18.2 CONSTRUCTS AND USES THEREOF
#1049B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#1050HETERODIMERIC PROTEINS WITH FC MUTATIONS
#1051TREATMENT INVOLVING ANTIGEN VACCINATION AND BINDING AGENTS BINDING TO PD-L1 AND CD137
#1052NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS AND METHODS OF MAKING SAME
#1053Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
#1054GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF
#1055ANTI-B7-H4 CONSTRUCTS AND USES THEREOF
#1056ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS
#1057USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR
#1058Methods for modulating an immune response
#1059METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS
#1060DOSAGE REGIME
#1061THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
#1062PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND APPLICATION THEREOF
#1063CD137 BINDING MOLECULES AND USES THEREOF
#1064FUSION PROTEINS AND USES THEREOF
#1065PHARMACEUTICAL COMPOSITION
#1066Bacterial Biomarker
#1067ANTI-CD47/ANTI-PD-L1 ANTIBODY AND APPLICATIONS THEREOF
#1068BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITONS AND METHODS THEREOF, FOR TREATMENT OF CANCER AND OTHER DISEASES
#1069BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
#1070ANTIBODIES FOR USE IN THERAPY
#1071ANTIBODY FRAGMENTS CONJUGATED TO PEG-PLGA NANOPARTICLES IMPROVE IMMUNOTHERAPY AGAINST CANCER CELLS
#1072ANTI-PD-L1 ANTIBODIES
#10734-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
#1074NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS
#1075COMBINATION OF AN AHR-INHIBITOR AND AN PD1-INHIBITOR ANTIBODY AND ITS USE IN THE TREATMENT OF CANCER
#1076Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof
#1077BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#1078Combination taxoid nanoemulsion with immunotherapy in cancer
#1079Diagnostic and therapeutic methods for cancer
#1080Anti-PD-L1 antibodies and anti-PD-L1/IL10 fusion proteins
#1081IN-SERIES SYNTHETIC RECEPTOR AND-GATE CIRCUITS FOR EXPRESSION OF A THERAPEUTIC PAYLOAD BY ENGINEERED CELLS
#1082Optimization of Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof
#1083Tetravalent bispecific antibody against PD-1 and PD-L1
#1084HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
#1085CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
#1086TREATMENT WITH A BISPECIFIC ANTIBODY THAT BINDS CTLA4 AND PD1
#1087Engineered immunostimulatory bacterial strains and uses thereof
#1088A BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
#1089Anti-VTCN1 antibodies and antibody drug conjugates
#1090COMPOSITIONS AND METHODS FOR GAMMA DELTA TCR REPROGRAMMING USING FUSION PROTEINS
#1091ANTI-PD-L1 ANTIBODIES
#1092ARTICLES OF MANUFACTURE COMPRISING ANTI PD-L1 ANTIBODIES AND THEIR USE IN THERAPY
#1093MESENCHYMAL STEM CELLS TO ENHANCE ANTI-TUMOR ACTIVITY OF IMMUNOTHERAPY
#1094HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#1095SELECTION OF PATIENTS FOR COMBINATION THERAPY
#1096Chimeric molecules providing targeted costimulation for adoptive cell therapy
#1097BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
#1098Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules
#1099Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#1100TARGETED TGFß INHIBITION
#1101Therapy for the Treatment of Cancer
#1102CHIMERIC ANTIGEN RECEPTOR AND IMMUNE EFFECTOR CELL EXPRESSING CHIMERIC ANTIGEN RECEPTOR
#1103Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
#1104ANTI-PD-L1 ANTIBODIES AND METHODS OF USING THE SAME FOR DETECTION OF PD-L1
#1105Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
#1106NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF
#1107Anti-human programmed death-1 monoclonal antibody
#1108COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
#1109CD73 compounds
#1110ANTI-PD-L1 ANTIBODY FORMULATIONS
#1111CAR-T cells targeting glioma stem cells for the treatment of glioblastoma multiforme
#1112MULTISPECIFIC NANOBODIES CHIMERIC ANTIGEN RECEPTOR AND T-CELL ENGAGER, NUCLEIC ACID, EXPRESSING CELL THEREOF, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, AND METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELL
#1113ANTI-TIGIT ANTIBODIES, MULTISPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF USING THE SAME
#1114BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-Beta
#1115Nant Cancer Vaccine
#1116ANTI-PDL1 ANTIBODIES AND USES THEREOF
#1117ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF
#1118Checkpoint blockade and microsatellite instability
#1119TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TLR MODULATOR
#1120ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE
#1121Bispecific GD2 and B7H3 Binding Molecules and Methods of Use
#1122COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
#1123REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF
#1124BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT
#1125ANTI-B7-H3 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF
#1126B7-H4 ANTIBODIES AND METHODS OF USE THEREOF
#1127BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
#1128ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF
#1129ANTI-CD3 ANTIBODIES AND METHODS OF USE
#1130METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES
#1131PD-L1 BINDING MOLECULE
#1132PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF
#1133ANTI-HUMAN PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) ANTIBODY AND USE THEREOF
#1134HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF
#1135Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1)
#1136METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC DEVLIERY DEVICE
#1137haNK Cetuximab Combinations And Methods
#1138Chimeric antigen receptors, compositions and applications thereof
#1139THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#1140MULTISPECIFIC ANTIBODY
#1141Tri-specific binding molecules
#1142ANTI-PD-L1 ANTIGEN BINDING PROTEIN AND APPLICATION THEREOF
#1143ANTIBODIES SPECIFIC TO GLYCOSYLATED CTLA-4 AND METHODS OF USE THEREOF
#1144COMPOSITIONS AND METHODS FOR MAKING AND USING MULTISPECIFIC ANTIBODIES
#1145LAG-3 Antagonist Therapy for Melanoma
#1146COMBINATION THERAPY FOR TREATING CANCER
#1147USE OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY
#1148NOVEL ANTI-PD-L1 ANTIBODIES
#1149ANTI-ICOS ANTIBODIES
#1150Chimeric antigen receptor-modified NK-92 cells
#1151Combination Therapy Based on PD-1 Signaling Inhibitors
#1152TARGETING PD-L1 ON TUMOR CELLS
#1153ANTI-PD-L1 ANTIBODY AND PHARMACEUTICAL USE THEREOF
#1154USES OF ANTI-ICOS ANTIBODIES
#1155EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS
#1156DIAGNOSTIC AND THERAPEUTIC METHODS FOR TREATMENT OF HEMATOLOGIC CANCERS
#1157HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY
#1158Methods of treating melanoma with S-equol
#1159IMMUNOSTIMULATORY BACTERIA DELIVERY PLATFORMS AND THEIR USE FOR DELIVERY OF THERAPEUTIC PRODUCTS
#1160HIGH AFFINITY NANOBODIES TARGETING B7-H3 (CD276) FOR TREATING MULTIPLE SOLID TUMORS
#1161ANTI-ICOS ANTIBODIES
#1162Splicing modulator antibody-drug conjugates and methods of use
#1163SIALIDASE-PD-L1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
#1164ANTI-CD40 BINDING MOLECULES AND BI-SPECIFIC ANTIBODIES COMPRISING SUCH
#1165COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR
#1166ANTI-PD-L1 SINGLE-DOMAIN ANTIBODIES
#1167Methods of treatment using CCR8 antibodies
#1168METHODS OF TREATING PD-L1 EXPRESSING CANCER
#1169BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#1170Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
#1171METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES
#1172MULTI-TUMOR GENE SIGNATURE FOR SUITABILITY TO IMMUNO-ONCOLOGY THERAPY
#1173ANTI-TIGIT ANTIBODIES AND APPLICATION THEREOF
#1174METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
#1175HUMAN ANTI-PD-L1 PEPTIDE VACCINES AND METHODS OF THEIR USE
#1176INHIBITION OF ATF7IP AND SETDB1 FOR CANCER TREATMENT
#1177ANTI-PD-L1 ANTIBODIES
#1178METHODS OF TREATING COLORECTAL CANCER
#1179CLEC9A BINDING AGENTS
#1180NOVEL ANTI-CD40 ANTIBODIES
#1181A NOVEL ANTI-PD-L1/ANTI-LAG-3 BISPECIFIC ANTIBODY AND USES THEREOF
#1182ANTIBODY BINDING SPECIFICALLY TO B7-H3 AND USE THEREOF
#1183USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS
#1184CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
#1185Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
#1186Implantable Device for Sustained Release of a Macromolecular Drug Compound
#1187PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER
#1188COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
#1189SPLIT INTEIN AND PREPARATION METHOD FOR RECOMBINANT POLYPEPTIDE USING THE SAME
#1190Anti-galectin-9 antibodies and uses thereof
#1191INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE
#1192RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF
#1193TUMOR MUTATIONAL LOAD
#1194COMBINATION OF MASKED CTLA4 AND PD1/PDL1 ANTIBODIES FOR TREATING CANCER
#1195METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
#1196COMPOSITIONS AND METHODS FOR PREVENTING RECURRENCE OF CANCER
#1197Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#1198ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
#1199ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF
#1200ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER